Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POST-PRANDIAL HYPO-AVOID: Low-dose glucagon with automated insulin delivery to prevent exercise-induced hypoglycemia in type 1 diabetes
2025-523996-45-00Phase 4Authorised
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of dasiglucagon in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Change in plasma glucose from exercise initiation to nadir and through 2-hour post-exercise period. Planned start Mar 2026; status: authorised.
02
Drugs
dasiglucagon
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2025-523996-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523996-45-00.